TrialCancer chemotherapy and pharmacology2020

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.

Masahito Kotaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.